Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024 - Biomea Fusion (NASDAQ:BMEA)

New clinical data from all dosing cohorts (n=62) initiated to date from the escalation portion of COVALENT-111 and long-term (26 weeks) follow-up data of the 200 mg dosed cohorts will be featured during an oral Poster

Related Keywords

United States ,Italy ,Chunyi Zhao ,Twitter ,Facebook ,Securities Exchange ,Biomea Fusion Inc ,Exchange Commission ,Linkedin ,Poster Discussion Presentation ,Poster Viewing Presentations ,International Conference ,Advanced Technologies ,Submission Number ,E Poster Discussion ,Durable Glycemic Control ,Treatment Period ,E Poster Viewing Session ,Key Observations ,Escalation Portion ,Covalent Menin Inhibitor ,Case Studies ,Securities Act ,Securities Exchange Act ,Exchange Act ,Biomea Fusion ,Investor Relations ,Corporate Development ,Media Relations ,Neera Chaudhary ,Chief Commercial Officer ,